Showing posts with label Malaria. Show all posts
Showing posts with label Malaria. Show all posts

Monday, 19 August 2013

Malaria could be tested early by cheap, portable device

Featured Article
Academic Journal
Main Category: Medical Devices / Diagnostics
Also Included In: Tropical Diseases;  Blood / Hematology
Article Date: 19 Aug 2013 - 3:00 PDT Current ratings for:
Malaria could be tested early by cheap, portable device
not yet ratednot yet rated

A device that measures electrical properties of red blood cells is able to detect if they are infected with malaria in the early stages. The researchers hope their findings will lead to a portable and low-cost, yet highly sensitive device that can diagnose malaria on the spot using just a drop of blood.

Anantha Chandrakasan and colleagues from the Massachusetts Institute of Technology (MIT) write about how they developed and tested their experimental microfluidic device in the journal Lab Chip.

The device spreads the drop of blood on an electrode that can count individual cells as they stream past, and it can also take very accurate readings of their impedance or electrical resistance.

In previous studies, the team had already established that diseases like malaria alter the electrical properties of red blood cells.

Chandrakasan, who specializes in developing low-power electronic devices, told the press:

"Ultimately the goal would be to create a postage stamp-sized device with integrated electronics that can detect if a person has malaria and at what stage."

The researchers believe the same technology can be used to diagnose other diseases that change the electrical properties of red blood cells.

Malaria is caused by five strains of Plasmodium, a parasite that lives in the gut of the female Anopheles mosquito and passes to humans through her bite.

For this study, the researchers investigated the strain P. falciparum. When the parasite enters the human bloodstream, it invades red blood cells, making then more magnetic and more rigid.

These changes can be detected by various diagnostic devices, but they do not occur until the parasite has reached a more advanced stage, when the red blood cells have started sticking to small blood vessels, blocking circulation and causing severe symptoms.

The new device is sensitive to another property that is measurable in the earliest parasite stage, the ring stage. The property it measures is electrical resistance or impedance.

Chandrakasan, who is a principal investigator at MIT's Microsystems Technology Laboratories (MTL), and the Joseph F. and Nancy P. Keithley professor of electrical engineering, and colleagues managed to make the device so sensitive it can take very accurate measurements of the size and phase of electrical impedance of individual cells.

They also managed to find a way to stop the cells sticking to each other, and they eliminated interfering signals from the electrode substrate that the blood cells flow over.

In their study report, they describe how they tested the device on four types of cells: uninfected cells and cells containing the parasite in three different stages of development, known as ring, trophozoite and schizont.

Although the device was not sensitive enough to reliably differentiate the different stages of parasite development, the researchers were able to combine the measures mathematically so it could reliably differentiate between uninfected and infected cells, including those containing the ring stage of the parasite.

Matthias Marti, assistant professor of immunology and infectious diseases at the Harvard School of Public Health, did not take part in the study. But he describes the device as "really cool" because it can spot the difference between unifected red blood cells and blood cells infected with the parasite even when it is still very small and before it has had a chance to alter the cells very much.

The researchers hope their work will quickly lead to a portable and cheap testing kit that can rapidly diagnose malaria in places that have no labs and trained staff.

Although rapid diagnosis kits for malaria are starting to appear and are promising to overtake the traditional way of diagnosing malaria that requires a trained technician to examine blood smears under a microscope, these are not very sensitive.

"For a new device to be meaningful in the field, it would have to be more sensitive than these traditional approaches, as well as cheap and quick," says Marti.

The team is now working on converting the experimental device into something that can be realistically used in the field. For that, it will have to be portable, disposable and cheap.

They say it will also be interesting to see if they could use the device to detect malaria infection at the stage when the parasite is mature enough to pass to other humans, through mosquito bites.

Malaria: 100% protection in early vaccine trial

Written by Catharine Paddock PhD


Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today Visit our medical devices / diagnostics section for the latest news on this subject.

Electric impedance microflow cytometry for characterization of cell disease states; E. Du, Sungjae Ha, Monica Diez-Silva, Ming Dao, Subra Suresh, and Anantha P. Chandrakasan; Lab Chip 2013; DOI: 10.1039/C3LC50540E; Abstract/summary.

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Paddock, Catharine. "Malaria could be tested early by cheap, portable device." Medical News Today. MediLexicon, Intl., 19 Aug. 2013. Web.
19 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Malaria could be tested early by cheap, portable device'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Saturday, 17 August 2013

Malaria DNA vaccine demonstrates robust immune responses in animal models

Main Category: Tropical Diseases
Also Included In: Immune System / Vaccines
Article Date: 16 Aug 2013 - 2:00 PDT Current ratings for:
Malaria DNA vaccine demonstrates robust immune responses in animal models
not yet ratednot yet rated

Inovio Pharmaceuticals, Inc. have announced that its SynCon® DNA vaccine containing multiple malaria antigens delivered via its CELLECTRA® electroporation device demonstrated strong and durable antibody and T-cell immune responses in small animals and non-human primates. With these strong preclinical results, Inovio plans to initiate a phase I/IIa clinical trial next year.

These results appear in the American Society for Microbiology's peer-reviewed journal, Infection & Immunity, in a paper entitled: "Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using pDNA," authored by Inovio researchers and collaborators.

The World Health Organization estimated that in 2010 there were more than 200 million cases of malaria and almost 700,000 deaths due to malaria infection, the majority affecting young children in Africa. To date, the most advanced malaria vaccine candidate RTS,S, an adjuvanted recombinant protein vaccine, has not shown substantial protection in the key trial age group of infants. Scientists believe that a more effective malaria vaccine should generate both strong antibody and potent T-cell immune responses.

In this study, Inovio researchers and collaborators designed a highly optimized DNA vaccine composed of four sporozoite and liver-stage malaria antigens using Inovio's SynCon technology. These antigens were chosen because of their important role in the control or elimination of malaria infection. Delivered using Inovio's CELLECTRA delivery system, this malaria vaccine generated robust and long-lasting T-cell responses in both mice and non-human primates. Moreover, these vaccine-produced T-cells exhibited the functional ability to kill and eliminate malaria-infected cells. Researchers also found vaccine-induced CD8+, or "killer T-cells," in the liver, which is essential for rapid elimination of liver-stage malaria parasites. The Inovio DNA/electroporation platform has demonstrated in prior preclinical and human studies the ability to induce potent immune responses to multiple antigens; in this study, robust and sustained antibody responses to all four malaria antigens were observed, a strong indication for a preventive response in humans.

Inovio plans to initiate a phase I/IIa clinical trial in 2014 to test Inovio's DNA vaccine and electroporation technology in approximately 30 individuals as part of a "challenge trial" involving controlled human malaria infection. Volunteers will be administered Inovio's vaccine, then exposed to the malaria parasite through the bite of infected mosquitoes to see whether this approach prevents infection. If deemed successful, this trial would provide valuable information that may further the development of a vaccine against malaria and lead to larger efficacy studies in the field.

Dr. J. Joseph Kim, President and CEO of Inovio, said, "Published data from two clinical studies has demonstrated that Inovio's products generated best-in-class T-cell immune responses. Using the same synthetic vaccine technology that produced clinical candidates against HPV, HIV, and influenza and achieved potent antibody and T-cell immune responses against these targets, we have now generated strong immunology data with our malaria vaccine in non-human primates. We are excited to advance toward the very important healthcare goal of conquering malaria."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our tropical diseases section for the latest news on this subject.

"Inducing humoral and cellular responses to multiple sporozoite and liver stage malaria antigens using pDNA" Infection & Immunity, Published ahead of print 29 July 2013, doi: 10.1128/IAI.00180-13

About Inovio Pharmaceuticals, Inc.

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Pharmaceuticals, About Inovio. "Malaria DNA vaccine demonstrates robust immune responses in animal models." Medical News Today. MediLexicon, Intl., 16 Aug. 2013. Web.
16 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Malaria DNA vaccine demonstrates robust immune responses in animal models'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here